Global Thoracic Aortic Stent Grafts Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Thoracic Aortic Stent Grafts Market Size

• The global thoracic aortic stent grafts market size was valued at USD 787.99 Million in 2025 and is expected to reach USD 1060.30 Million by 2033, at a CAGR of 3.78% during the forecast period
• The market growth is largely fueled by the rising prevalence of thoracic aortic aneurysms and dissections, along with increasing adoption of minimally invasive endovascular procedures, leading to improved clinical outcomes and reduced hospital stays compared to open surgical repair
• Furthermore, growing demand for advanced, safer, and patient-specific treatment options, combined with continuous technological advancements in stent graft design, imaging guidance, and delivery systems, is establishing thoracic aortic stent grafts as the preferred treatment approach. These converging factors are accelerating the uptake of Thoracic Aortic Stent Grafts solutions, thereby significantly boosting the industry’s growth

Thoracic Aortic Stent Grafts Market Analysis

• Thoracic aortic stent grafts, used in the endovascular repair of thoracic aortic aneurysms and dissections, are critical medical devices in modern cardiovascular care due to their minimally invasive nature, reduced surgical risk, and faster patient recovery compared to open surgical procedures
• The escalating demand for thoracic aortic stent grafts is primarily driven by the rising prevalence of cardiovascular diseases, increasing geriatric population, and growing preference for endovascular repair techniques among clinicians, supported by continuous advancements in stent graft materials and delivery systems
• North America dominated the thoracic aortic stent grafts market with the largest revenue share of approximately 38.6% in 2025, supported by advanced healthcare infrastructure, high adoption of minimally invasive vascular procedures, favorable reimbursement policies, and a strong presence of leading medical device manufacturers, with the U.S. accounting for the majority of regional demand
• Asia-Pacific is expected to be the fastest-growing region in the thoracic aortic stent grafts market during the forecast period, registering a CAGR of around 8.9%, driven by improving healthcare access, rising incidence of aortic disorders, increasing healthcare expenditure, and expanding adoption of advanced endovascular technologies in countries such as China and India
• The metal segment dominated the largest market revenue share of approximately 63.1% in 2025, driven by its superior mechanical strength, durability, and long-term clinical reliability in thoracic endovascular aortic repair (TEVAR) procedures

Report Scope and Thoracic Aortic Stent Grafts Market Segmentation

Thoracic Aortic Stent Grafts Market Trends

Advancements in Minimally Invasive Endovascular Repair Technologies

• A significant and accelerating trend in the global thoracic aortic stent grafts market is the continuous advancement in endovascular repair technologies, aimed at improving procedural outcomes, reducing surgical trauma, and expanding patient eligibility for minimally invasive treatment of thoracic aortic diseases
  • For instance, leading manufacturers such as Medtronic, W. L. Gore & Associates, and Terumo have been focusing on the development of next-generation thoracic stent grafts with enhanced conformability, improved sealing zones, and greater flexibility to accommodate complex aortic anatomies
• Technological innovations such as low-profile delivery systems, improved radial force control, and fenestrated or branched stent graft designs are enabling physicians to treat a wider range of thoracic aortic aneurysms and dissections with greater precision
• The growing adoption of minimally invasive endovascular procedures over open surgical repair is further reinforcing demand, as these procedures offer reduced recovery times, lower complication rates, and shorter hospital stays
• This trend toward device innovation and procedural refinement is reshaping clinical practice in vascular surgery and interventional cardiology, driving steady adoption of thoracic aortic stent grafts across both developed and emerging healthcare markets

Thoracic Aortic Stent Grafts Market Dynamics

Driver

Rising Prevalence of Thoracic Aortic Aneurysms and Preference for Minimally Invasive Procedures

• The increasing incidence of thoracic aortic aneurysms, dissections, and traumatic aortic injuries, particularly among the aging population, is a major driver supporting growth of the thoracic aortic stent grafts market globally
  • For instance, the growing clinical adoption of thoracic endovascular aortic repair (TEVAR) as a first-line treatment option in many healthcare systems has significantly increased demand for advanced stent graft devices
• Compared to conventional open surgery, TEVAR offers advantages such as lower perioperative mortality, reduced blood loss, and faster patient recovery, making it the preferred treatment approach for high-risk and elderly patients
• Improvements in diagnostic imaging, early disease detection, and expanded clinical guidelines have further increased the number of patients eligible for endovascular intervention
• In addition, rising healthcare investments and improving access to specialized vascular care facilities in emerging economies are contributing to broader adoption of thoracic aortic stent grafts worldwide

Restraint/Challenge

High Device Costs and Procedure-Related Complications

• One of the key challenges in the thoracic aortic stent grafts market is the high cost of stent graft devices and associated endovascular procedures, which can limit accessibility in cost-sensitive healthcare systems and developing regions
  • For instance, advanced thoracic stent graft systems with specialized designs for complex anatomies significantly increase overall treatment costs, placing a financial burden on hospitals and patients where reimbursement coverage is limited
• In addition, potential complications such as endoleaks, stent migration, graft collapse, and the need for long-term imaging follow-up can affect clinical outcomes and increase post-procedural care costs
• The requirement for highly skilled vascular surgeons and specialized infrastructure, including advanced imaging and hybrid operating rooms, further restricts adoption in smaller or under-resourced medical centers
• Overcoming these challenges will depend on cost optimization, continued device innovation, expanded reimbursement support, and improved physician training, which are critical for sustained growth of the global thoracic aortic stent grafts market

Thoracic Aortic Stent Grafts Market Scope

The market is segmented on the basis of type and end user.

• By Type

On the basis of type, the Thoracic Aortic Stent Grafts market is segmented into Metal and Polymer. The metal segment dominated the largest market revenue share of approximately 63.1% in 2025, driven by its superior mechanical strength, durability, and long-term clinical reliability in thoracic endovascular aortic repair (TEVAR) procedures. Metal-based stent grafts, primarily composed of nitinol and stainless steel, provide excellent radial force, flexibility, and resistance to fatigue, which are critical for managing complex thoracic aortic aneurysms and dissections. Their proven ability to maintain vessel patency and ensure secure fixation contributes to high procedural success rates. Strong physician preference, extensive clinical evidence, and widespread availability across tertiary hospitals further reinforce dominance. Continuous technological improvements in deployment systems and sealing performance also support sustained adoption of metal stent grafts.

The polymer segment is expected to witness the fastest growth at a CAGR of 10.2% from 2026 to 2033, driven by rising innovation in advanced polymer materials and increasing demand for flexible, lightweight stent graft solutions. Polymer-based stent grafts offer enhanced conformability, improved biocompatibility, and reduced vessel trauma, making them suitable for select patient populations. Growing emphasis on minimally invasive procedures and next-generation endovascular devices is accelerating adoption. Ongoing R&D, hybrid material development, and favorable early clinical outcomes are further boosting growth. As manufacturers continue to refine polymer-based designs, this segment is projected to expand rapidly over the forecast period.

• By End User

On the basis of end user, the Thoracic Aortic Stent Grafts market is segmented into Hospitals, Ambulatory Surgical Centers, Medical Centers, and Others. The hospitals segment accounted for the largest market revenue share of approximately 69.4% in 2025, driven by the high volume of thoracic aortic aneurysm and dissection cases treated in hospital settings. Hospitals possess advanced imaging infrastructure, hybrid operating rooms, and specialized vascular and cardiothoracic surgeons required for complex TEVAR procedures. The availability of intensive care units and post-operative monitoring facilities further supports hospital-based procedures. Higher reimbursement coverage and the ability to manage high-risk patients also contribute to segment dominance. In addition, the presence of multidisciplinary care teams and access to a broad range of stent graft technologies reinforce hospitals as the primary end users.

The ambulatory surgical centers segment is expected to register the fastest CAGR of 9.6% from 2026 to 2033, driven by the growing shift toward minimally invasive procedures and cost-effective care delivery models. Advancements in stent graft technology and simplified procedural techniques are enabling select thoracic interventions to be performed in outpatient settings. ASCs offer shorter hospital stays, reduced procedural costs, and faster patient recovery, making them increasingly attractive. Rising healthcare cost pressures and favorable reimbursement policies are supporting this transition. As procedural safety and efficiency continue to improve, adoption of thoracic stent grafts in ambulatory surgical centers is expected to grow steadily.

Thoracic Aortic Stent Grafts Market Regional Analysis

• North America dominated the thoracic aortic stent grafts market with the largest revenue share of approximately 38.6% in 2025, supported by advanced healthcare infrastructure, high adoption of minimally invasive endovascular procedures, and strong reimbursement frameworks
• The region benefits from a high prevalence of thoracic aortic aneurysms and dissections, along with early diagnosis and timely surgical intervention
• Strong clinical expertise, widespread availability of hybrid operating rooms, and rapid adoption of next-generation stent graft technologies further support market leadership

U.S. Thoracic Aortic Stent Grafts Market Insight

The U.S. thoracic aortic stent grafts market accounted for the majority share within North America in 2025, driven by high procedure volumes and strong physician preference for endovascular repair over open surgery. The country benefits from well-established vascular surgery programs, advanced imaging capabilities, and favorable reimbursement for minimally invasive interventions. Increasing incidence of aortic aneurysms among the aging population and patients with cardiovascular risk factors continues to drive demand. In addition, ongoing clinical trials, rapid FDA approvals, and the presence of key industry players significantly contribute to sustained market expansion.

Europe Thoracic Aortic Stent Grafts Market Insight

The Europe thoracic aortic stent grafts market is projected to expand at a steady CAGR during the forecast period, driven by rising awareness of aortic diseases and increasing adoption of minimally invasive vascular procedures. Strong regulatory standards and emphasis on patient safety promote the use of clinically validated stent graft systems. Growth is supported by an aging population, increasing prevalence of cardiovascular disorders, and expanding access to advanced endovascular treatments. Countries across Western Europe continue to invest in healthcare modernization, supporting broader adoption in hospital and specialty care settings.

U.K. Thoracic Aortic Stent Grafts Market Insight

The U.K. thoracic aortic stent grafts market is expected to grow at a notable CAGR, supported by the National Health Service’s (NHS) focus on reducing surgical invasiveness and improving patient outcomes. Increasing use of TEVAR procedures for thoracic aortic aneurysms and dissections is driving market demand. Centralized vascular centers, improved referral pathways, and enhanced diagnostic imaging capabilities further contribute to growth. Ongoing investments in cardiovascular care infrastructure are expected to sustain market expansion over the forecast period.

Germany Thoracic Aortic Stent Grafts Market Insight

The Germany thoracic aortic stent grafts market is anticipated to expand at a considerable CAGR, driven by strong clinical expertise, high procedural volumes, and advanced hospital infrastructure. Germany’s emphasis on technological innovation and evidence-based medical practice supports the adoption of next-generation stent graft systems. Favorable reimbursement policies and early adoption of advanced endovascular techniques further strengthen market growth. The country’s leadership in medical device research and manufacturing also contributes to increased availability and utilization of thoracic stent grafts.

Asia-Pacific Thoracic Aortic Stent Grafts Market Insight

The Asia-Pacific thoracic aortic stent grafts market is expected to be the fastest-growing region, registering a CAGR of around 8.9% during the forecast period, driven by improving healthcare access and rising incidence of aortic disorders. Rapid urbanization, lifestyle-related cardiovascular risk factors, and growing awareness of minimally invasive treatment options are accelerating adoption. Increasing healthcare expenditure and expansion of tertiary care hospitals are further supporting market growth. The region is witnessing rising adoption of advanced endovascular technologies across both public and private healthcare systems.

Japan Thoracic Aortic Stent Grafts Market Insight

The Japan thoracic aortic stent grafts market is experiencing steady growth, supported by a rapidly aging population and high prevalence of cardiovascular diseases. Strong clinical expertise and early adoption of advanced endovascular procedures drive demand for thoracic stent grafts. Japan’s healthcare system emphasizes minimally invasive treatments that reduce hospital stay and procedural risk. Continuous technological innovation and strong regulatory oversight further contribute to sustained market expansion.

China Thoracic Aortic Stent Grafts Market Insight

The China thoracic aortic stent grafts market held the largest revenue share within Asia-Pacific in 2025, driven by expanding healthcare infrastructure and increasing diagnosis of aortic diseases. Government investment in hospital modernization and growing adoption of minimally invasive vascular procedures are key growth drivers. Rising healthcare spending, increasing availability of trained specialists, and the presence of domestic medical device manufacturers support market expansion. As access to advanced endovascular therapies improves, China is expected to remain a key contributor to regional growth.

Thoracic Aortic Stent Grafts Market Share

The Thoracic Aortic Stent Grafts industry is primarily led by well-established companies, including:

• Medtronic plc (Ireland)
• W. L. Gore & Associates, Inc. (U.S.)
• Terumo Corporation (Japan)
• Cook Medical (U.S.)
• MicroPort Scientific Corporation (China)
• Endologix LLC (U.S.)
• Artivion, Inc. (formerly CryoLife) (U.S.)
• Lombard Medical (U.K.)
• Braile Biomédica (Brazil)
• JOTEC GmbH (Germany)
• Bolton Medical (U.S.)
• Meril Life Sciences (India)

Latest Developments in Global Thoracic Aortic Stent Grafts Market

• In March 2023, Bolton Medical, Inc. received U.S. FDA approval for its RelayPro Thoracic Stent-Graft System, which includes nitinol and polyester stent components used to repair damage in the descending thoracic aorta, expanding treatment options for endovascular aortic repair in the United States
• In September 2023, MicroPort Endovastec obtained approval from the Thailand Food and Drug Administration (TFDA) for three aortic intervention products, including the Hercules Thoracic Stent Graft System with a low-profile delivery system for thoracic and abdominal aortic disease, enabling use in Thailand’s clinical settings
• In June 2023, Terumo Aortic’s RelayPro Thoracic Stent-Graft received FDA approval in the United States for the treatment of thoracic dissection and aneurysm, featuring a low-profile design that broadens pathology coverage and procedural flexibility
• In April 2025, Gore & Associates announced FDA approval for four new large-diameter tapered designs of the Gore TAG Conformable Thoracic Stent Graft with Active Control System (sizes up to 45 × 37 mm), enhancing options for treating diverse thoracic aortic anatomies
• In June 2025, Gore & Associates received FDA approval for the TAG Thoracic Branch Endoprosthesis (TBE) for use in zones 0 and 1 of the aorta, expanding its indication for endovascular management of aortic arch and descending thoracic lesions while preserving flow to branch vessels
• In March 2025, Cook Medical announced the commercial launch of its Zenith Alpha 2 (ZTA2) Thoracic Endovascular Graft in the United States, following regulatory approval. The device builds on Cook’s established Zenith platform with enhancements designed to support thoracic endovascular aortic repair procedures

SKU-64072